Scientific Programme
Bradykinin Symposium
Thursday, 15 September 2022
12:00-12:45
12:45-13:00
Lunch
Welcome
Session I: Bradikinin Basics
13:00-13:25
13:25-13:50
13:50-14:15
14:15-14:45
The generation of Bradykinin
Breakdown of Bradykinin and its Metabolites
The kallikrein-kinin system and it´s neighbors
Coffee Break
Session II: News in BK
14:45-15:00
15:00-15:15
15:15-15:30
15:30-15:45
15:45-16:00
16:00-17:30
Peptide fragments of Bradykinin show unexpected biological
The pathophysiology of Bradykinin in COVID
Bradykinin-target therapies in SARS-CoV-2 infection
Crosstalk mast cell – kinin system
The endothelial response to Bradykinin and other vasoactive substances
Coffee Break
Session III: Short oral presentations
17:30-18:20
18:20-18:25
18:25-19:00
19:00-23:00
tba
Closing Remarks
Walk to Dinner Location
Scientific Dinner
Friday, 16 September 2022
8:00-8:15
8:15-8:20
Coffee and Welcome
Summary day 1
Session IV: BK and angioedema
8:20-8:35
8:35-8:50
8:50-9:05
9:05-9:20
9:20-9:35
9:35-10:05
Classification of angioedema: The 2022 approach
How to measure Bradykinin and other kinins in angioedema patients
Clinical and Laboratory evaluation of Bradykinin mediated angioedema
Genetics and its use for diagnostics in angioedema
AAE: The neglected little brother
Coffee Break
Session V: Short Oral Presentations
10:05-10:55
10:55-11:30
tba
Coffee Break
Session VI: Hereditary angioedema
11:30-11:40
11:40-11:55
11:55-12:00
12:00-12:15
12:15-12:35
12:35-13:30
Comorbidities in HAE
HAE with normal C1-INH: Focus on non-Bradykinin mediated forms
On demand treatment from the patients’ perspective in real life
Outcome measures of acute therapy for hereditary angioedema
Modern prophylaxis in real life
Lunch
Session VII: tba
13:30-14:20
14:20-15:00
tba
Poster Session
HAE worldwide
15:00-15:20
15:20-15:40
15:40-16:00
16:00-16:20
16:20-16:35
16:35-16:50
HAE in India: A country with 30000 patients?
Prophylaxis as standard treatmen? What can we learn from Canada?
All for the patient: HAEi & ACARE
Speculating about future treatments
Conclusions: What did we hear? What take we home?
Closing remarks
by May 2022
